Considering the direct suppressive effect of pre-treating platelets with CDNF on AA-induced platelet activation, the therapeutic protocol was adapted to involve the pre-treatment of platelets from hemorrhagic stroke patients with CDNF at concentrations of 0.5, 1, or 2 μg/mL for 10 min prior to co-culturing with BV2 cells for 6 h. Here, CDNF is linked to hemorrhagic stroke.